A combination of MCAK inhibitors with IL6R inhibitors may be a potential way to increase the efficacy of both drugs, while counteracting some of the pro-tumorigenic effects of CIN [80]. The gene discussed is IL6R; the disease is cervical squamous intraepithelial neoplasia.